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Treatment of aortic graft infection remains a sur-
gical challenge. In 1993, Kieffer et al1 reported their
results of 43 patients in whom they performed in
situ replacement with arterial allografts. This
method is now widely used in our country.
However, degeneration and dilatation of arterial
allografts are well-known late complications requir-
ing close follow-up of these patients.2 Until recent-
ly, surgical replacement with a new graft was the only
available treatment of such dilatations. We report the
endovascular repair of an aneurysmal allograft
degeneration by means of a bifurcated stent graft.
CASE REPORT
Progressive enlargement of an arterial allograft was
detected in a 65-year-old man during follow-up. In 1981,
this patient underwent an aortobifemoral bypass grafting for
intermittent claudication. The graft was made of woven
Dacron. In 1991, infection of the graft was detected, and
aortic graft–enteric fistula was discovered during surgery.
Bacterial contamination of the graft was massive with sever-
al microorganisms cultured: Enterococcus species, Staphylococcus
aureus, and Candida albicans. Surgical treatment consisted
of the removal of all prosthetic material, suturing of the duo-
denum, in situ replacement with a fresh arterial allograft, and
prolonged antibiotherapy. The arterial allograft was a fresh
graft harvested during a multiorgan procedure. This was a
composite graft: the proximal portion was a segment of
descending thoracic aorta, the distal portion was an arterial
segment including the distal part of the abdominal aorta and
both iliac arteries, and both segments were anastomosed
end-to-end before implantation. The allograft was fixed 2
cm below the renal arteries in an end-to-end fashion. Post-
operative course was marked by bilateral hydronephrosis
treated with ureteral catheters. At 3 months postoperatively,
intestinal occlusion necessitated surgical open repair. From
this point on, late follow-up was uneventful, the patient did
not have any claudication, and regular computed tomogra-
phy (CT) scans were obtained to detect any enlargement of
the allograft. This enlargement appeared progressively. The
initial diameter of the body of the graft was 28 mm, and after
the first year, annual growth of the diameter was 3 mm,
reaching 5 mm the last year before the procedure. At 7-year
follow-up, the proximal part of the allograft became truly
aneurysmal with a diameter of 48 mm. On examination, the
patient did not complain of pain on abdominal palpation. All
peripheral pulses were present, and the patient did not have
any claudication. The results of blood tests were in the nor-
mal range without any inflammatory syndrome, and C-reac-
tive protein was normal. We did not use any other test to rule
out recurrent infection of the allograft because most likely,
late degeneration of the graft was the cause of the dilatation.
An aorto-arteriography was performed with a marked
catheter, showing a dilatation of the body of the allograft
and the presence of a long neck (> 4 cm) above the
aneurysm (Fig 1). The branches of the allograft were patent
with a good runoff. Occlusion of the inferior mesenteric
artery and both internal iliac arteries was noted. On the CT,
the aneurysmal dilatation was limited to the body of the
allograft, and mural thrombus was present in the aneurys-
mal sac. Endovascular treatment was proposed to this
patient. A bifurcated stent graft was placed through a right
groin incision and a left percutaneous puncture of the
femoral artery. We used the Vanguard endoprosthesis
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(Boston Scientific Corporation, Boston, Mass). This is a
self-expandable device with a thermic form memory. The
main body of the device was placed through the right
femoral artery. Its proximal diameter was 22 mm, the distal
diameter was 10 mm, and the length was 153 mm. The
proximal endograft attachment site was just below the renal
arteries in the native aorta, completely covering the proxi-
mal part of the allograft. The contralateral limb was intro-
duced percutaneously through a 10-F sheath placed in the
left femoral artery. The limb was 100 mm long and had a
diameter of 10 mm. Gentle manual inflation was carried out
with a 10/4 balloon. Retrograde control angiography
showed bilateral distal endoleaks that were treated with
extensions of increasing diameters (12-14 mm) in both iliac
limbs of the allograft. Final control showed complete exclu-
sion of the aneurysmal dilatation of the allograft without
any visible leak (Fig 2). The procedure time was 130 min-
utes, with 35 minutes of fluoroscopy and a 170-mL injec-
tion of contrast medium. After the procedure, recovery was
uneventful. The patient was discharged on the fourth day
after the procedure, and a control CT scan with contrast
injection showed perfect patency of the device without any
apparent leak. At 6-month follow-up, the patient was
asymptomatic. Duplex scan showed good patency of the
device without any leak, and a new control CT showed per-
fect exclusion of the aneurysmal sac with a slight reduction
of the aneurysmal diameter (45 mm) (Fig 3).
DISCUSSION
Treatment of aortoenteric graft fistula remains a
surgical challenge with early mortality ranging from
19% to 38%.3,4 Recurrent infection and limb loss occur
in a substantial number of patients. Two different ther-
apeutic approaches are currently used: first, complete
resection of the infected graft, associated with surgical
closure of the aorta and extra-anatomic bypass graft-
ing, and second, in situ reconstruction after removal of
the infected prosthesis, with the use of either a new
prosthetic graft or arterial or venous allografts. Since
1990,5 we have treated 14 patients with an infected
infrarenal aortic prosthetic graft; six of them had an
aortic graft–enteric fistula. Prolonged and extensive
follow-up of these patients was maintained to detect
any late deterioration of the allografts.2,6 This deterio-
ration can occur after two modes: stenosis and dilata-
tion. The first is mainly due to intimal hyperplasia in
the branches of the graft leading to progressive occlu-
sion. Its incidence can reach 20%,4 and it can be treat-
ed with either ballon angioplasty or reoperation. The
dilatation of the graft seems to be less frequent and
could be due to the use of the descending thoracic aor-
tic allografts.4 In our patient, progressive enlargement
Fig 1. Preoperative aortography showing a long proximal
neck above the aneurysmal degeneration of the allograft.
Fig 2. Final angiography showing complete exclusion of
the aneurysm.
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of the body of the graft led us to an aggressive
approach regarding the aneurysmal allograft. Surgical
reoperation would have been the “classic” mode of
treatment for this patient, with in situ replacement of
the body of the allograft with a new prosthetic graft in
an aseptic field. Such reoperation is often challenging
because of dense adhesions and hemorrhagic risk. An
endovascular approach was discussed to reduce the
surgical morbidity. Since the original work by Parodi et
al,7 many publications have stressed the feasibility of
endovascular treatment of aortic aneurysms.8-10
Recent reports have emphasized the incidence of early
and late complications, the most frequent being
endoaneurysmal endoleaks. Late rupture has also been
reported without any evidence of endoleak.11 Despite
these problems, endovascular treatment of aortic
aneurysm remains an attractive method, particularly
for elderly patients with a high surgical risk. We have
treated 50 patients using either the Vanguard or the
Talent device. The present case was particularly suit-
able for endovascular treatment because of the follow-
ing reasons: the infrarenal neck was long (> 4 cm), the
iliac branches of the allograft were linear, and the inter-
nal iliac arteries were occluded. Furthermore, this case
compares favorably with other postaortic reconstruc-
tion aneurysmal complications such as anastomotic
pseudoaneurysms. Because the aneurysmal degenera-
tion was restricted to the body of the allograft, we
could treat a straight fusiform sac without particular
caution or difficulty because of the renal or internal
iliac arteries. The placement of the endovascular device
was then particularly easy, and immediate exclusion of
the aneurysm was obtained. Care was taken to overlap
the anastomosis between the allograft and the native
aorta to allow placement of the proximal attachment
site in the native aorta and avoid any potential late
complications such as a pseudoaneurysm between the
aorta and the allograft. The main concerns about
endovascular treatment of allograft aneurysmal dilata-
tion are related to the future of the allograft itself.
First, the part of the allograft covered by the endovas-
cular device could become ischemic because of the
radial forces applied by the device. Second, the remain-
ing part of the graft (ie, the branches) could also
degenerate mainly because of progressive stenosis 
or occlusion. To our knowledge, the interactions
between an endovascular device and an allograft are
not known. We did observe medial alterations (necro-
sis) in a sheep model of aortic endovascular grafting
with oversizing of the device (M. Matem, unpublished
data, Sep 1996). Furthermore, late stenosis of the
branches of arterial allografts may occur. We do not
know yet if the presence of the endovascular device
inside these branches will cause further hyperplasia,
particularly below the distal attachment site. Aggres-
sive follow-up is obviously needed including CT and
duplex scanning.
In summary, to our knowledge this is the first
case of late aneurysmal degeneration of an arterial
allograft treated with an endovascular device. This
method could become the treatment of choice for
such late degenerations, avoiding challenging surgi-
cal reoperations.
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Fig 3. Control CT scan at 6 months showing graft’s limb
patency and complete exclusion of the aneurysm.
